Medtech
Nephros, Inc., a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets, announced preliminary financial results for the quarter ended June 30, 2019.
SonoCloud ultrasound device for glioblastoma patients will be tested for first time at US clinical sites
Immigration has been a central concern of President Donald Trump. Since taking office, his administration has put forth a number of policies to restrict the number of immigrants allowed each year, as well as from what nations those immigrants can come.
Polarean Imaging plc, the clinical stage medical-imaging technology company, with a proprietary drug-device combination product for the visualisation of pulmonary function in the magnetic resonance imaging market, announces its audited final results for the year ended 31 December 2018.
Cambridge, Mass.-based Vaxess Technologies is inching closer to developing a bandage-like product that will be able to administer vaccines and other therapeutics through the skin.
The Management Board of MagForce AG has resolved and successfully completed, with the approval of the Supervisory Board, on basis of the authorization provided for in the Company’s articles of association, an increase of the registerd share capital of the Company from currently EUR 26,463,802.00 to EUR 27,640,274.00 by issuing 1,176,472 new no-par value bearer shares under exclusion of the shareholders’ statutory subscription rights.
MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results as of and for the year ended December 31, 2018 as well as operative highlights.
The U.S. Food and Drug Administration (FDA)’s Circulatory System Devices Panel is in the middle of two days of presentations and meetings regarding mortality rates associated with the use of paclitaxel-coated balloons (DCBs) and paclitaxel-eluting stents (DESs). The discussions are noting missing data and conflicting analysis.
Virtue® SEB is expected to become a flagship therapeutic product for Terumo and will strengthen its broad US and global portfolio of interventional solutions
Medical device manufacturing remains a strong market, driven by technological developments, an aging population and increases in chronic and lifestyle diseases.
PRESS RELEASES